secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-062020
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma reports Q3 2023 cash of $105.6M; Phase 3 sarcoidosis study enrollment to complete early Q2 2024
--------------------------------------------------------------------------------

- Cash, cash equivalents and investments totaled $105.6M as of September 30, 2023.
- Phase 3 EFZO-FIT study in pulmonary sarcoidosis expects enrollment completion early Q2 2024; positive DSMB safety review.
- Phase 2 EFZO-CONNECT study in systemic sclerosis-ILD dosed first patient.
- R&D expenses were $10.3M, G&A $2.6M, collaboration revenue $0.4M from Kyorin agreement.
- Updated cash runway guidance: sufficient through BLA filing for efzofitimod in sarcoidosis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017023062020/0000950170-23-062020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017023062020/life-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer